抗体-药物偶联物(ADCs)的研发进展及其关键影响因素探讨

The Research and Development of Antibody Drug Conjugates(ADCs)and Discussion on its Key Influencing Factors

在肿瘤治疗过程中,小分子化疗药物对肿瘤细胞具备高度杀伤力但靶向性较差,副作用较严重;而单克隆抗体虽靶向性良好但抗肿瘤活性较弱,使用剂量较大。抗体-药物偶联物(Antibody-drag conjugates,ADCs)的出现正好使两者互补,代表了新一代抗体技术的发展方向,被认为是抗肿瘤的有力武器。文章从ADCs的3个组成部分即抗体、化学药物及连接物3方面讨论其研发过程中的影响因素并介绍ADCs的安全隐患、企业研发现状、研发难点及挑战。展望了ADCs的发展趋势。

In cancer treatment,small molecular chemotherapetic drugs have significant damage but with poor targeting property and serious side effects on tumor cells,monoclonal antibodies have good targeting property but with weak antitumor activity and have to use larger doses.Antibody drug conjugates（ADCs） just make them complementary and represent the development direction of a new generation of antibody technology,which are considered to be the useful weapon against cancer.In this article,three components of ADCs,namely antibodies,chemical drugs and linkers were discussed and influencing factors of RD of ADCs and security risks,enterprise development situation,difficulties,challenges and trends for ADCs were also discussed.